Hexobarbital
(Redirected from Evipal)
Hexobarbital is a barbiturate derivative with anesthetic and sedative properties. It was first synthesized in the early 20th century and has been used in various medical applications, particularly as a general anesthetic and hypnotic agent.
Chemical Properties[edit | edit source]
Hexobarbital, also known as 5-(1-cyclohexen-1-yl)-1,5-dimethylbarbituric acid, is a white crystalline powder that is soluble in water and alcohol. Its chemical formula is C12H16N2O3, and it has a molecular weight of 236.27 g/mol.
Pharmacology[edit | edit source]
Hexobarbital acts on the central nervous system (CNS) by enhancing the activity of the gamma-aminobutyric acid (GABA) receptor, which is the primary inhibitory neurotransmitter in the CNS. This action results in sedation, hypnosis, and anesthesia. The drug has a relatively short duration of action compared to other barbiturates, making it suitable for procedures requiring brief periods of anesthesia.
Medical Uses[edit | edit source]
Hexobarbital has been used primarily as a general anesthetic for short surgical procedures. It has also been employed as a sedative and hypnotic for the treatment of insomnia and other sleep disorders. However, due to the development of newer and safer anesthetic agents, the use of hexobarbital has declined significantly.
Side Effects[edit | edit source]
Common side effects of hexobarbital include drowsiness, dizziness, and nausea. In higher doses, it can cause respiratory depression, hypotension, and bradycardia. Long-term use can lead to tolerance, dependence, and withdrawal symptoms.
Metabolism and Excretion[edit | edit source]
Hexobarbital is metabolized in the liver by the cytochrome P450 enzyme system and is excreted primarily in the urine. The drug has a half-life of approximately 3 to 6 hours.
History[edit | edit source]
Hexobarbital was first synthesized in the 1930s and was widely used during the mid-20th century. Its use has declined with the advent of newer anesthetic agents that offer improved safety profiles and fewer side effects.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
